Janux Therapeutics, Inc. (JANX) compared with its closest peers (XLO, XNCR, CBIO, CATX, PGEN). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Xilio Therapeutics and Xencor: named as a competitor in the 10-K.
| Company | Market Cap | P/E |
|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | $53.17M | — |
| Xencor, Inc. (XNCR) | $1.81B | — |
| Crescent Biopharma, Inc. (CBIO) | $717.99M | — |
| Perspective Therapeutics, Inc. (CATX) | $321.91M | — |
| Precigen, Inc. (PGEN) | $2.45B | — |
| Bolt Biotherapeutics, Inc. (BOLT) | $7.40M | — |
| Zenas BioPharma, Inc. (ZBIO) | $1.97B | — |
| Contineum Therapeutics, Inc. (CTNM) | $554.52M | — |
| Fate Therapeutics, Inc. (FATE) | $277.98M | — |
| Cullinan Therapeutics, Inc. (CGEM) | $1.32B | — |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
JANX overview · JANX earnings · JANX financials · JANX KPIs · JANX documents · JANX ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.